Präoperative Bestrahlung mit interstitiellem Radiohyperthermie-Boost bei Mammatumoren ≥3 cm

Hartmann, Karl; Audretsch, Werner; Carl, U. M.; Gripp, Stephan; Kolotas, C.; Muskalla, K.; Rezai, Mahdi; Schnabel, Thomas; Waap, I.; Zamboglou, N.; Schmitt, G.

doi:10.1007/bf03038468

Cited by 9 publications

(3 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The policy of resecting the tumor according to its pretreatment margins and the relatively large tumor diameters (median, 3 cm [chemotherapy group] and 5.5 cm [chemo-/radiotherapy group]) may be the reason for the relatively low breastpreserving rate of 50% in our protocol. In this context it has to be taken into consideration that in the past this policy resulted in a low rate of isolated locoregional recurrence [16,17].…”

Section: Discussionmentioning

confidence: 99%

Remission Rates in Breast Cancer Treated with Preoperative Chemotherapy and Radiotherapy

et al. 2003

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Remission Rates in Breast Cancer Treated with Preoperative Chemotherapy and Radiotherapy

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Inspired by Hartmann et al and Gardner et al, we intended to increase the probability of eradicating potentially invasive cells in the tumor bed and its surroundings [ 29 , 30 ]. Based on recent reports, we are still aware that HT sensitizes the cells to radiation and, thus, should enhance the treatment efficacy [ 31 ].…”

Section: Discussionmentioning

confidence: 99%

Thermally boosted interstitial high-dose-rate brachytherapy in high-risk early-stage breast cancer conserving therapy — large cohort long-term results

Chicheł,

Burchardt,

Kluska

et al. 2023

Rep Pract Oncol Radiother.

View full text Add to dashboard Cite

Background Early-stage high-risk breast cancer (BC) is standardly treated with breast-conserving therapy (BCT), combined with systemic therapy and radiotherapy (RT) ± tumor bed boost, e.g., with interstitial high-dose-rate brachytherapy (HDR-BT). To improve local recurrence rate (LRR), BT radiosensitization (thermal boost, TB) with interstitial microwave hyperthermia (MWHT) may be an option. The paper aims to report a retrospective single-institutional study on 5- and 10-year local control (LC), distant metastasis-free survival (DMFS), disease-free survival (DFS), overall survival (OS), cosmetic outcome (CO), and late toxicity (fibrosis, fat necrosis) after thermally enhanced HDR-BT boost to the BC tumor bed. Materials and methods In 2006–2018, 557 early-stage (I–IIIA) high-risk BC patients were treated with BCT. If indicated, they were administered systemic therapy, then referred for 40.0–50.0 Gy whole breast irradiation (WBI) and 10 Gy interstitial HDR-BT boost (group A). Eligible patients had a single MWHT session preceding BT (group B). Based on present risk factors (RF), medium-risk (1–2 RF) and high-risk subgroups (≥ 3 RF) were formed. Patients were standardly checked, and control mammography (MMG) was performed yearly. Breast cosmesis (Harvard scale) and fibrosis were recorded. LC, DMFS, DFS, and OS were statistically analyzed. Results Out of 557 patients aged 57 years (26–84), 364 (63.4%) had interstitial HDR-BT boost (group A), and 193 (34.6%) were preheated with MWHT (group B). Patients in group B had a higher clinical stage and had more RFs. The median follow-up was 65.9. Estimated 5-year and 10-year LC resulted in 98.5% and 97.5%, respectively. There was no difference in LC, DMFS, DFS, and OS between groups A and B and between extracted high-risk subgroups A and B. Five- and ten-year OS probability was 95.4% and 88.0%, respectively, with no difference between groups A and B. Harvard criteria-based CO assessment revealed good/excellent cosmesis in 74.9–79.1%. Tumor bed hardening was present in 40.1–42.2%. Asymptomatic fat necrosis-related macrocalcifications were detected in 15.6%, more frequently in group B (p = 0.016). Conclusions Thermally boosted or not, HDR-BT was locally highly effective as part of combined treatment. Five- and ten-year LC, DMFS, DFS, and OS were high and equally distributed between the groups, although TB was prescribed in more advanced one with more RFs. TB did not influence CO and fibrosis. TB added to late toxicity regarding asymptomatic fat necrosis detected on MMG.

show abstract

“…Die Kombination aus präoperativer Chemotherapie und Radiatio hat sich in Studien bezüglich der Tumorreduktion als effektiver als die alleinige Chemotherapie herausgestellt [6,7]. Die interstitielle Radiotherapie ist bereits mit Erfolg beim Mammakarzinom angewandt worden [8,9]. Bei der Zwischenauswertung einer laufenden Studie mit 52 Patientinnen [10] war nach primärer Chemobrachytherapie in 82 % eine brusterhaltende Operation möglich.…”

unclassified

MR-Mammographie zur Responsekontrolle bei primärer Chemobrachytherapie des BET-inoperablen Mammakarzinoms

Hlawatsch¹,

Kuner²,

Teifke³

et al. 2001

Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr

Self Cite

View full text Add to dashboard Cite

show abstract

Präoperative Bestrahlung mit interstitiellem Radiohyperthermie-Boost bei Mammatumoren ≥3 cm

Abstract: In about 50%, breast conservation was achieved by chemotherapy, radiotherapy and hyperthermia. The low isolated local recurrence rate of 0.6% (1/158) has to be substantiated by further follow-up.

Cited by 9 publications

References 8 publications

Remission Rates in Breast Cancer Treated with Preoperative Chemotherapy and Radiotherapy

Remission Rates in Breast Cancer Treated with Preoperative Chemotherapy and Radiotherapy

Thermally boosted interstitial high-dose-rate brachytherapy in high-risk early-stage breast cancer conserving therapy — large cohort long-term results

MR-Mammographie zur Responsekontrolle bei primärer Chemobrachytherapie des BET-inoperablen Mammakarzinoms

Contact Info

Product

Resources

About